Ipsen posts 8% rise in first-half 2012 sales

28 August 2012

French drugmaker Ipsen (Euronext: IPN) yesterday reported first-half 2012 financial results with 8% growth in consolidated sales to 629.8 million euros ($788.3 million). Operating income was 125.7 million euros, or 20.0% of sales, and consolidated net profit fell 1.5% to 90.5 million euros.

For the full year 2012, the company expects specialty care drug sales to grow in the upper range of 8% to 10%; Primary care drug sales to decrease by around 15%; and recurring adjusted operating margin of about 15%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK